DUBLIN – Oxford University spinout Vaccitech Ltd. raised £20 million (US$27.3 million) in a series A round that will enable it to complete an ongoing phase IIb trial of a universal influenza vaccine and a phase II trial of a therapeutic prostate cancer vaccine within the next two years.